JAK

Janus kinase

JAK

JAK Isoform Specific Products:

JAK Isoform Comparison

JAK Related Products (423)
Recombinant Proteins (5)
Antibodies (8)
JAK Isoform Comparison

By Effects:	Control (1) Substrate (1) Ligand (1) Inhibitors (387) Agonists (2) Degraders (4) Antagonist (1) Activators (9) Modulators (4) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-107594

Benzene hexabromide	Inhibitor	≥98.0%
Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation.

HY-U00318

JAK-IN-11	Inhibitor	98.62%
JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment. JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-RS07018

JAK2 Human Pre-designed siRNA Set A	Inhibitor
JAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for JAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

JAK2 Human Pre-designed siRNA Set A JAK2 Human Pre-designed siRNA Set A

HY-RS07015

JAK1 Human Pre-designed siRNA Set A	Inhibitor
JAK1 Human Pre-designed siRNA Set A contains three designed siRNAs for JAK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

JAK1 Human Pre-designed siRNA Set A JAK1 Human Pre-designed siRNA Set A

HY-40354D

(3R,4S)-Tofacitinib	Inhibitor	99.88%
(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.

HY-U00277

JAK-IN-10	Inhibitor	99.72%
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders. JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-156409

ABBV-712	Inhibitor	99.94%
ABBV-712 is a selective and orally active inhibitor of Tyrosine kinase 2 (TYK2). ABBV-712 has EC₅₀ values of 0.01, 0.19, and 0.17 μM for TYK2 JH2, TYK2 cells and human whole blood, respectively. ABBV-712 has anti-inflammatory activity and can be used in the research of autoimmune diseases.

HY-111471

JAK-IN-5	Inhibitor
JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.

HY-130247A

Flonoltinib TFA	Inhibitor	99.77%
Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity.

HY-152080

TUL01101	Inhibitor	99.71%
TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis.

HY-18710

BMS-066	Inhibitor	99.09%
BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC₅₀s of 9 nM and 72 nM, respectively.

HY-100754C

Ritlecitinib tosylate	Inhibitor	99.77%
Ritlecitinib tosylate is an orally active and selective JAK3 inhibitor with an IC₅₀ of 33.1 nM. Ritlecitinib tosylate is used for inflammatory and autoimmune diseases research.

HY-153701

JAK-IN-26	Inhibitor	98.00%
JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC₅₀=17.2 nM).

HY-153440

JAK-IN-25	Inhibitor	98.44%
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research.

HY-W004283R

Pentadecanoic acid (Standard)	Inhibitor
α-Linolenic acid (Standard) is the analytical standard of α-Linolenic acid. This product is intended for research and analytical applications. α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer.

HY-W394903

GS-829845	Inhibitor	99.91%
GS-829845 is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life.

HY-161618

MJ04	Inhibitor	98.08%
MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC₅₀ of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD₅₀ >2 g/kg).

HY-161683

Tyk2-IN-19	Inhibitor	98.62%
Tyk2-IN-19 (compound 1) is an orally active and blood-brain barrier (BBB) permeable Tyk2 inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases.

HY-N0697R

Crocin (Standard)	Inhibitor
Crocin (Standard) is the analytical standard of Crocin. This product is intended for research and analytical applications. Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through JAK pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .

HY-N3710

Dehydrocrenatidine	Inhibitor	≥98.0%
Dehydrocrenatidine, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.

JAK Isoform Comparison

JAK1

JAK2

JAK3

Tyk2

JAK

JAK Degraders, Ligands, Inducers, Inhibitors, Activators & Modulators

Product Name	JAK1	JAK2	JAK3	Tyk2	JAK	Purity

Ruxolitinib	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM		99.99%
Tofacitinib	JAK1, IC₅₀: 112 nM	JAK2, IC₅₀: 20 nM	JAK3, IC₅₀: 1 nM			99.99%
Upadacitinib	JAK1, IC₅₀: 0.043 μM	JAK2, IC₅₀: 0.2 μM	JAK3, IC₅₀: 2.3 μM	Tyk2, IC₅₀: 4.7 μM		99.98%
Deucravacitinib	JAK1 JH2, IC₅₀: 1 nM			Tyk2 JH2, IC₅₀: 0.2 nM		99.87%
Baricitinib	JAK1, IC₅₀: 5.9 nM	JAK2, IC₅₀: 5.7 nM	JAK3, IC₅₀: 560 nM	Tyk2, IC₅₀: 53 nM		99.97%
(R)-9b		JAK2		Tyk2		99.51%
JAK2-IN-11		JAK2-WT, IC₅₀: ≤10 nM JAK2-V617F, IC₅₀: ≤10 nM
Fedratinib		JAK2, IC₅₀: 3 nM JAK2(V617F), IC₅₀: 3 nM				99.87%
Ritlecitinib			JAK3, IC₅₀: 33.1 nM			99.80%
Ruxolitinib phosphate	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM		99.97%
Butyzamide		JAK2				99.62%
Pacritinib	JAK1, IC₅₀: 1280 nM	JAK2^V617F, IC₅₀: 19 nM JAK2^wt, IC₅₀: 23 nM	JAK3, IC₅₀: 520 nM	Tyk2, IC₅₀: 50 nM		99.93%
Tofacitinib citrate	JAK1, IC₅₀: 112 nM	JAK2, IC₅₀: 20 nM	JAK3, IC₅₀: 1 nM			99.94%
WP1066		JAK2				99.77%
Filgotinib	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 28 nM	JAK3, IC₅₀: 810 nM	Tyk2, IC₅₀: 116 nM		99.44%
Momelotinib	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM			99.37%
Abrocitinib	JAK1, IC₅₀: 29 nM	JAK2, IC₅₀: 803 nM		Tyk2, IC₅₀: 1253 nM		99.26%
Itacitinib	JAK1					99.97%
AZD-1480	JAK1, IC₅₀: 1.3 nM	JAK2, IC₅₀: <0.4 nM				99.91%
RO8191	JAK1					≥99.0%
Peficitinib	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM		99.43%
AT9283		JAK2, IC₅₀: 1.2 nM	JAK3, IC₅₀: 1.1 nM			99.67%
CHZ868		JAK2, IC₅₀: 110 nM				99.56%
Cucurbitacin I		JAK2				99.44%
Ruxolitinib (S enantiomer)					JAK	99.94%
Pyridone 6	Murine JAK1, IC₅₀: 15 nM	JAK2, IC₅₀: 1 nM	JAK3, IC₅₀: 5 nM	Tyk2, IC₅₀: 1 nM		98.13%
Baricitinib phosphate	JAK1, IC₅₀: 5.9 nM	JAK2, IC₅₀: 5.7 nM	JAK3, IC₅₀: 560 nM	Tyk2, IC₅₀: 53 nM		99.97%
Delgocitinib	JAK1, IC₅₀: 2.8 nM	JAK2, IC₅₀: 2.6 nM	JAK3, IC₅₀: 13 nM	Tyk2, IC₅₀: 58 nM		99.61%
Lestaurtinib		JAK2, IC₅₀: 0.9 nM				99.17%
Golidocitinib	JAK1, IC₅₀: 73 nM					99.54%
(E/Z)-Zotiraciclib		JAK2, IC₅₀: 73 nM				99.96%
Gandotinib		JAK2, IC₅₀: 3 nM	JAK3, IC₅₀: 48 nM	Tyk2, IC₅₀: 44 nM		99.86%
Brepocitinib	JAK1, IC₅₀: 17 nM	JAK2, IC₅₀: 77 nM	JAK3, IC₅₀: 6.9 μM			99.97%
Cerdulatinib	JAK1, IC₅₀: 12 nM	JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 8 nM	Tyk2, IC₅₀: 0.5 nM		99.06%
Fedratinib hydrochloride hydrate		JAK2, IC₅₀: 3 nM JAK2(V617F), IC₅₀: 3 nM				99.92%
NSC 42834		JAK2-WT, IC₅₀: 15 μM JAK2-V617F, IC₅₀: 28 μM
Decernotinib	JAK1, Ki: 11 nM	JAK2, Ki: 13 nM	JAK3, Ki: 2.5 nM	Tyk2, Ki: 11 nM		99.91%
VVD-118313	JAK1					99.75%
Oclacitinib monomaleate	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 99 nM	Tyk2, IC₅₀: 84 nM		99.87%
Broussonin E		JAK2				98.18%
JANEX-1			JAK3, IC₅₀: 78 μM			99.63%
BMS-911543	JAK1, IC₅₀: 75 nM	JAK2, IC₅₀: 1.1 nM	JAK3, IC₅₀: 360 nM	Tyk2, IC₅₀: 66 nM		98.23%
Radotinib		JAK2				98.92%
AZ960		JAK2, Ki: 0.45 nM JAK2, IC₅₀: <3 nM	JAK3, IC₅₀: 9 nM
BD750			JAK3			99.10%
Oclacitinib	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 99 nM	Tyk2, IC₅₀: 84 nM		99.59%
CEP-33779		JAK2, IC₅₀: 1.8 nM	JAK3, IC₅₀: 150 nM			99.77%
SJ988497		JAK2				98.05%
TG101209		JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 169 nM			99.22%
RGB-286638		JAK2, IC₅₀: 50 nM				99.70%
SJ10542		JAK2, DC₅₀: 14 nM	JAK3, DC₅₀: 11 nM			99.92%
Ilginatinib	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		99.94%
NVP-BSK805	JAK1 JH1, IC₅₀: 31.63 nM	JAK2 JH1, IC₅₀: 0.48 nM FL JAK2 V617F, IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM	JAK3 JH1, IC₅₀: 18.68 nM	TYK2 JH1, IC₅₀: 10.76 nM		99.89%
SAR-20347	JAK1, IC₅₀: 23 nM	JAK2, IC₅₀: 26 nM	JAK3, IC₅₀: 41 nM	Tyk2, IC₅₀: 0.6 nM
XL019		JAK2, IC₅₀: 2.2 nM	JAK3, IC₅₀: 214.2 nM			99.65%
BMS-986202				Tyk2 JH2, IC₅₀: 0.19 nM Tyk2 JH2, Ki: 0.02 nM		99.92%
Brepocitinib P-Tosylate	JAK1, IC₅₀: 17 nM	JAK2, IC₅₀: 77 nM	JAK3, IC₅₀: 6.9 μM			99.98%
Desmethoxyyangonin		JAK2				99.47%
Londamocitinib	JAK1, IC₅₀: 0.54 nM					98.98%
Flonoltinib	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM			99.79%
TCS 21311	JAK1, IC₅₀: 1.017 μM	JAK2, IC₅₀: 2.55 μM	JAK3, IC₅₀: 8 nM			99.18%
Momelotinib sulfate	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM			98.06%
JAK2-IN-6		JAK2, IC₅₀: 22.86 μg/mL				99.14%
JAK2 JH2 binder-1		JAK2 JH2, Kd: 37.1 nM
Reticuline		JAK2				98.91%
Protosappanin A		JAK2				99.98%
TyK2-IN-2				Tyk2 JH2, IC₅₀: 7 nM		98.64%
Ivarmacitinib	JAK1	JAK2	JAK3	Tyk2		99.82%
JAK3-IN-6			JAK3, IC₅₀: 0.15 nM			99.90%
Tyk2-IN-5				Tyk2 JH2, Ki: 0.086 nM		99.35%
Itacnosertib		JAK2, IC₅₀: 8540 nM				99.06%
ZM39923 hydrochloride	JAK1, pIC₅₀: 4.4		JAK3, pIC₅₀: 7.1			98.19%
Cerdulatinib hydrochloride	JAK1, IC₅₀: 12 nM	JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 8 nM	Tyk2, IC₅₀: 0.5 nM		99.89%
FM-381			JAK3, IC₅₀: 127 pM			99.58%
NVP-BSK805 dihydrochloride	JAK1 JH1, IC₅₀: 31.63 nM	JAK2 JH1, IC₅₀: 0.48 nM FL JAK2 V617F, IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM	JAK3 JH1, IC₅₀: 18.68 nM	TYK2 JH1, IC₅₀: 10.76 nM		99.36%
G5-7		JAK2				99.55%
RGB-286638 free base		JAK2, IC₅₀: 50 nM				98.07%
WHI-P154			JAK3, IC₅₀: 1.8 μM			99.39%
Solcitinib	JAK1, IC₅₀: 9.8 nM					99.51%
JAK-IN-23	JAK1, IC₅₀: 8.9 nM	JAK2, IC₅₀: 15 nM	JAK3, IC₅₀: 46.2 nM			98.90%
JAK3-IN-1	JAK1, IC₅₀: 896 nM	JAK2, IC₅₀: 1050 nM	JAK3, IC₅₀: 4.8 nM			99.31%
PF-06263276	JAK1, IC₅₀: 2.2 nM	JAK2, IC₅₀: 23.1 nM	JAK3, IC₅₀: 59.9 nM	Tyk2, IC₅₀: 29.7 nM		99.38%
SJ1008030 formic		JAK2
GSK2646264		JAK2, pIC₅₀: 5				98.39%
Lomedeucitinib				Tyk2		99.75%
(E/Z)-Zotiraciclib hydrochloride		JAK2				99.90%
Itacitinib adipate	JAK1					99.18%
BI-1622			JAK3			98.97%
(E/Z)-Zotiraciclib citrate		JAK2				98.06%
WHI-P97			JAK3, IC₅₀: 11 μM			99.70%
SJ1008030 TFA		JAK2				99.81%
SC99		JAK2				98.96%
Deuruxolitinib	JAK1	JAK2				99.18%
Ilginatinib hydrochloride	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		98.92%
Itacnosertib hydrochloride		JAK2, IC₅₀: 8540 nM				99.43%
JAK-IN-3	JAK1, IC₅₀: 5 nM	JAK2, IC₅₀: 70 nM	JAK3, IC₅₀: 3 nM	Tyk2, IC₅₀: 34 nM		98.92%
Filgotinib maleate	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 28 nM	JAK3, IC₅₀: 810 nM	Tyk2, IC₅₀: 116 nM		99.88%
(2R,5S)-Ritlecitinib			JAK3, IC₅₀: 144.8 nM			99.77%
(R,R)-VVD-118313	JAK1					99.54%
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK1, Ki: 0.7 nM	JAK2, Ki: 0.7 nM	JAK3, Ki: 0.4 nM	Tyk2, Ki: 4.8 nM		99.80%
Ilginatinib maleate	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		99.87%
GLPG3667	JAK1, IC₅₀: 38 nM	JAK2, IC₅₀: 7.3 nM	JAK3, IC₅₀: 374 nM	Tyk2, IC₅₀: 2.3 nM		99.81%
JAK2-IN-7	JAK1, IC₅₀: 42 nM	JAK2, IC₅₀: 3 nM	JAK3, IC₅₀: 94 nM	Tyk2, IC₅₀: 75 nM		99.15%
JAK1-IN-8	JAK1, IC₅₀: <500 nM	JAK2, IC₅₀: 500-1000 nM	JAK3, IC₅₀: >5000 nM
HG-7-85-01	JAK1, IC₅₀: 120 nM					99.94%
TCJL37				Tyk2, Ki: 1.6 nM		99.89%
JAK-IN-20	JAK1, IC₅₀: 7 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 14 nM			99.63%
Tyk2-IN-7				Tyk2 JH2, IC₅₀: 0.00053 μM Tyk2 JH2, Ki app: 0.00007 μM		99.62%
JAK1-IN-4	JAK1, IC₅₀: 85 nM	JAK2, IC₅₀: 12.8 μM				99.26%
GLPG0634 analog	JAK1, IC₅₀: <100 nM	JAK2, IC₅₀: <100 nM	JAK3, IC₅₀: <100 nM	Tyk2, IC₅₀: <100 nM		98.07%
SD-1029		JAK2
TYK2-IN-12	JAK1, Ki: 45.9 nM	JAK2, Ki: 21.93 nM	JAK3, Ki: 6.63 nM	Tyk2, Ki: 0.51 nM		98.81%
JAK-IN-11					JAK	98.62%
JAK-IN-10					JAK	99.72%
Flonoltinib TFA	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM			99.77%
TUL01101	JAK1, IC₅₀: 3 nM	JAK2, IC₅₀: 37 nM	JAK3, IC₅₀: 1517 nM	Tyk2, IC₅₀: 36 nM		99.71%
BMS-066				Tyk2, IC₅₀: 72 nM		99.09%
JAK-IN-25	JAK1, IC₅₀: 21 nM	JAK2, IC₅₀: 8 nM	JAK3, IC₅₀: 1051 nM	Tyk2, IC₅₀: 6 nM		98.44%
GS-829845	JAK1					99.91%
MJ04	JAK1, IC₅₀: 192.64 nM	JAK2, IC₅₀: 255.88 nM	JAK3, IC₅₀: 2.03 nM			98.08%
YLIU-4-105-1		JAK2
JAK-IN-21	JAK1, IC₅₀: 1.73 nM	JAK2, IC₅₀: 2.04 nM JAK2-V617F, IC₅₀: 109 nM		Tyk2, IC₅₀: 62.9 nM		99.72%
FM-479			JAK3			99.2%
JAK1/2-IN-1	JAK1, IC₅₀: 0.4 nM	JAK2, IC₅₀: 8.1 nM				98.36%
ZT55		JAK2, IC₅₀: 0.031 μM				99.51%
ZM 449829	JAK1, pIC₅₀: 4.7		JAK3, pIC₅₀: 6.8			99.73%
Ruxolitinib sulfate	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM
Bayer-18				Tyk2
SD-1008		JAK2				99.10%
Upadacitinib tartrate tetrahydrate	JAK1, IC₅₀: 0.043 μM	JAK2, IC₅₀: 0.2 μM	JAK3, IC₅₀: 2.3 μM	Tyk2, IC₅₀: 4.7 μM
Peficitinib hydrobromide	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM
JAK-IN-4					JAK
JAK3 covalent inhibitor-1			JAK3, IC₅₀: 11 nM
NVP-BSK805 trihydrochloride	JAK1 JH1, IC₅₀: 31.68 nM	JAK2 JH1, IC₅₀: 0.48 nM JAK2(V617F), IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM		TYK2 JH1, IC₅₀: 18.68 nM
AT9283 lactic acid		JAK2, : 1.2 nM	JAK3, : 1.1 nM
Nezulcitinib					JAK
Pacritinib hydrochloride	JAK1, IC₅₀: 1280 nM	JAK2^V617F, IC₅₀: 19 nM JAK2^wt, IC₅₀: 23 nM	JAK3, IC₅₀: 520 nM	Tyk2, IC₅₀: 50 nM
JAK-IN-36	JAK1, IC₅₀: 2.2 nM
YSY01A		JAK2
LRRK2-IN-8				Tyk2, IC₅₀: 10-100 nM
Tyk2-IN-3				Tyk2, IC₅₀: 485 nM
Tyk2-IN-16				Tyk2 JH2, IC₅₀: <10 nM
MTP		JAK2
JAK-2/3-IN-3		JAK2, IC₅₀: 13.00 nM	JAK3, IC₅₀: 14.86 nM
JAK-2/3-IN-1		JAK2, Ki: <250 nM	JAK3, Ki: <250 nM
Peficitinib hydrochloride	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM
JAK-IN-30	JAK1, IC₅₀: 15 nM	JAK2, IC₅₀: 2 nM	JAK3, IC₅₀: 18 nM	Tyk2, IC₅₀: 2 nM
JAK1/STAT3-IN-1	JAK1
FAK-IN-22			JAK3, IC₅₀: 9.99 nM
JANEX-1 hydrochloride			JAK3, IC₅₀: 78 μM
Momelotinib dihydrochloride	JAK1	JAK2
Ten01	JAK1, IC₅₀: 5 nM
Thi-DPPY			JAK3, IC₅₀: 1.38 nM
JAK1/TYK2-IN-3	JAK1, IC₅₀: 37 nM	JAK2, IC₅₀: 140 nM	JAK3, IC₅₀: 362 nM	Tyk2, IC₅₀: 6 nM
PF-00956980	JAK1, IC₅₀: 2.2 μM	JAK2, IC₅₀: 23.1 μM	JAK3, IC₅₀: 59.9 μM
Tyk2-IN-20	JAK1, IC₅₀: <100 nM	JAK2, IC₅₀: <100 nM	JAK3, IC₅₀: <100 nM	Tyk2, IC₅₀: <5 nM
TK4b		JAK2, IC₅₀: 19.40 nM	JAK3, IC₅₀: 18.42 nM
JAK3-IN-9			JAK3, IC₅₀: 1.7 nM
LRRK2/NUAK1/TYK2-IN-1				Tyk2
JAK2-IN-1		JAK2
JAK3-IN-11	JAK1, IC₅₀: 1.32 μM	JAK2, IC₅₀: 1 μM	JAK3, IC₅₀: 1.7 nM
JAK-2/3-IN-2		JAK2, IC₅₀: 23.85 nM	JAK3, IC₅₀: 18.9 nM
DPPY			JAK3, IC₅₀: <10 nM
TYK2 ligand 2				Tyk2 JH2
JAK2/FLT3-IN-3		JAK2, IC₅₀: 2.01 nM	JAK3, IC₅₀: 104.40 nM
JAK2-IN-10		JAK2-V617F, IC₅₀: ≤10 nM
JAK1-IN-12	JAK1, IC₅₀: 0.0246 μM	JAK2, IC₅₀: 0.423 μM	JAK3, IC₅₀: 0.410 μM	Tyk2, IC₅₀: 1.12 μM
K882	JAK1
JAK1-IN-14	JAK1, IC₅₀: 12.6 nM	JAK2, IC₅₀: 135 nM
JAK1-IN-9	JAK1, IC₅₀: 72 nM	JAK2, IC₅₀: 839 nM
JAK3 covalent inhibitor-2			JAK3, IC₅₀: 7.2 nM
MS-1020			JAK3
JAK 3i	JAK1, IC₅₀: 1520 nM	JAK2, IC₅₀: 8680 nM	JAK3, IC₅₀: 0.43 nM
JAK2-IN-9		JAK2
NSC 33994		JAK2, IC₅₀: 60 nM (JAK2 Val617Phe kinase activity )
JI6			JAK3, IC₅₀: ~250 nM
Tyk2-IN-22	JAK1, IC₅₀: 148.6 nM		JAK3, IC₅₀: 883.3 nM	Tyk2, IC₅₀: 9.7 nM
JAK-IN-39	JAK1, IC₅₀: 0.05 nM	JAK2, IC₅₀: 1.18 nM	JAK3, IC₅₀: 0.03 nM
JAK/HDAC-IN-2	JAK1, IC₅₀: 27.15 nM	JAK2, IC₅₀: 5.32 nM	JAK3, IC₅₀: 594.8 nM	Tyk2, IC₅₀: 414.4 nM
JAK3/BTK-IN-6	JAK1, IC₅₀: >1000 nM	JAK2, IC₅₀: 657.9 nM	JAK3, IC₅₀: 0.4 nM	Tyk2, IC₅₀: >1000 nM
TK4g		JAK2, IC₅₀: 12.61 nM	JAK3, IC₅₀: 15.80 nM
JAK1-IN-10	JAK1
JAK2/TYK2-IN-1		JAK2, IC₅₀: 157 nM		Tyk2, IC₅₀: 9 nM
JAK3-IN-14		JAK2, IC₅₀: 600 nM	JAK3, IC₅₀: 38 nM			99.32%
Tyk2-IN-18				Tyk2 JH2, IC₅₀: <10 nM
Dual Cathepsin L/JAK-IN-1	JAK1, IC₅₀: 337.1 nM	JAK2, IC₅₀: 5.251 nM	JAK3, IC₅₀: 27.29 nM	Tyk2, IC₅₀: 172.6 nM
JAK3-IN-12	JAK1, IC₅₀: 18 nM	JAK2, IC₅₀: 42 nM	JAK3, IC₅₀: 9.5 nM
Tkip		JAK2
JAK-IN-34	JAK1, IC₅₀: 0.40 nM	JAK2, IC₅₀: 0.83 nM	JAK3, IC₅₀: 2.10 nM	Tyk2, IC₅₀: 1.95 nM
JAK-IN-38	JAK1, IC₅₀: 0.44 μM	JAK2, IC₅₀: 0.12 μM	JAK3, IC₅₀: 0.06 μM	Tyk2, IC₅₀: 0.03 μM
JAK-IN-38	JAK1, IC₅₀: 0.44 μM	JAK2, IC₅₀: 0.12 μM	JAK3, IC₅₀: 0.06 μM	Tyk2, IC₅₀: 0.03 μM
Zemprocitinib	JAK1, IC₅₀: 5.95 nM	JAK2, IC₅₀: 141.3 nM		Tyk2, IC₅₀: 119 nM		99.31%
5TTU			JAK3
Flonoltinib monomaleate	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM
Momelotinib mesylate	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM
ZM39923	JAK1, pIC₅₀: 4.4		JAK3, pIC₅₀: 7.1
NMS-P953		JAK2, IC₅₀: 0.008 μM
R-348 choline			JAK3
ON044580		JAK2-WT, IC₅₀: 1.23 μM JAK2-V617F, IC₅₀: 1.09 μM
NSC114792			JAK3
AS2553627	JAK1	JAK2	JAK3	Tyk2
TM-233		JAK2
JAK3-IN-7			JAK3, IC₅₀: 0.01 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.

JAK

JAK

JAK Isoform Specific Products:

JAK Isoform Specific Products:

JAK Related Products (423)

Recombinant Proteins (5)

Antibodies (8)

JAK Isoform Comparison

JAK Related Products (423):